These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 26628462)

  • 1. Reply to S. Iwase et al.
    Hofheinz RD; Burkholder I; Schneeweiss A
    J Clin Oncol; 2016 Feb; 34(4):392. PubMed ID: 26628462
    [No Abstract]   [Full Text] [Related]  

  • 2. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome.
    Iwase S; Ishiki H; Watanabe A; Shimada N; Chiba T; Kinkawa J; Tojo A
    J Clin Oncol; 2016 Feb; 34(4):391. PubMed ID: 26628471
    [No Abstract]   [Full Text] [Related]  

  • 3. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
    Hofheinz RD; Gencer D; Schulz H; Stahl M; Hegewisch-Becker S; Loeffler LM; Kronawitter U; Bolz G; Potenberg J; Tauchert F; Al-Batran SE; Schneeweiss A
    J Clin Oncol; 2015 Aug; 33(22):2444-9. PubMed ID: 26124485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Capecitabine-induced hyperpigmentation followed by hand-foot syndrome: a new case report].
    Agharbi FZ; Meziane M; Benhemmne H; Daoudi K; Elmesbahi O; Mikou O; Mernissi FZ
    Ann Dermatol Venereol; 2012 Mar; 139(3):221-2. PubMed ID: 22401689
    [No Abstract]   [Full Text] [Related]  

  • 5. Images in clinical medicine. Loss of fingerprints.
    Chavarri-Guerra Y; Soto-Perez-de-Celis E
    N Engl J Med; 2015 Apr; 372(16):e22. PubMed ID: 25875278
    [No Abstract]   [Full Text] [Related]  

  • 6. The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study.
    Ota M; Tatsumi K; Suwa H; Watanabe J; Watanabe K; Osada S; Tanaka K; Shoichi F; Ichikawa Y; Kunisaki C; Endo I
    Hepatogastroenterology; 2014 Jun; 61(132):1008-13. PubMed ID: 26158157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Breast cancer and the hand-foot syndrome].
    Llambrich C; Falcou MC; De Rycke Y; Cottu P; Carrié S; Medjbari M
    Soins; 2012 Jun; (766):25-8. PubMed ID: 22870762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unilateral hand-foot syndrome: does it take sides? Case report and literature review.
    Almeida da Cruz L; Hoff PM; Ferrari CL; Riechelmann RS
    Clin Colorectal Cancer; 2012 Mar; 11(1):82-4. PubMed ID: 21764392
    [No Abstract]   [Full Text] [Related]  

  • 9. [Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy].
    Yamagiwa K; Shigematsu T; Takeda K; Shirai M; Amemori K; Sunda K; Koike C; Yamada T
    Gan To Kagaku Ryoho; 2013 Dec; 40 Suppl 2():161-3. PubMed ID: 24712132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reply to F.V. Negri et al.
    Ye SL
    J Clin Oncol; 2015 Oct; 33(28):3220-1. PubMed ID: 26215937
    [No Abstract]   [Full Text] [Related]  

  • 11. A CDD polymorphism as predictor of capecitabine-induced hand-foot syndrome--letter.
    Ciccolini J; Evrard A; Lacarelle B
    Clin Cancer Res; 2012 Jan; 18(1):317. PubMed ID: 22215908
    [No Abstract]   [Full Text] [Related]  

  • 12. Hypertriglyceridaemia-induced pancreatitis: a contributory role of capecitabine?
    Chan HY; Ng CM; Tiu SC; Chan AO; Shek CC
    Hong Kong Med J; 2012 Dec; 18(6):526-9. PubMed ID: 23223655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Progress of study on prevention and treatment of xeloda induced hand-foot syndrome by measures of Chinese and Western medicine].
    Wang Y; Xu RR
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 Feb; 27(2):182-4. PubMed ID: 17343012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is pyridoxine helpful in preventing palmar-plantar erythrodysesthesia associated with capecitabine?
    Jeung HC; Chung HC
    Asia Pac J Clin Oncol; 2010 Sep; 6(3):141-3. PubMed ID: 20887492
    [No Abstract]   [Full Text] [Related]  

  • 15. [Hand-foot syndrome with capecitabine therapy].
    Marini A; Hengge UR
    Hautarzt; 2007 Jun; 58(6):532-6. PubMed ID: 16897045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Assessment of hand-foot syndrome in cancer outpatients undergoing chemotherapy].
    Takeda K; Shigematsu T; Shirai M; Yamagiwa K; Amamori K; Sunda K; Yamanda T
    Gan To Kagaku Ryoho; 2012 Dec; 39 Suppl 1():74-6. PubMed ID: 23268906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of AboundTM for hand-foot syndrome caused by capecitabine].
    Fujii C; Imamura H; Fukunaga M; Kamigaki S; Kimura Y; Kawase T; Kawabata R; Fujino M; Iseki C; Hamaguchi Y; Yamamoto E; Ishizaka T; Hachino Y
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):2457-9. PubMed ID: 24394143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capecitabine-induced hand-foot syndrome and cutaneous hyperpigmentation in an elderly vitiligo patient.
    Tavares-Bello R
    J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1434-5. PubMed ID: 17958867
    [No Abstract]   [Full Text] [Related]  

  • 19. The use of capecitabine in cancer: management of the hand foot syndrome.
    Sudoyo AW
    Acta Med Indones; 2005; 37(3):174-6. PubMed ID: 16110178
    [No Abstract]   [Full Text] [Related]  

  • 20. Topical henna ameliorated capecitabine-induced hand-foot syndrome.
    Ilyas S; Wasif K; Saif MW
    Cutan Ocul Toxicol; 2014 Sep; 33(3):253-5. PubMed ID: 24021017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.